| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015356 |
| Receipt No. | R000017839 |
| Official scientific title of the study | A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2M |
| Date of disclosure of the study information | 2014/10/08 |
| Last modified on | 2016/10/07 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2M | |
| Title of the study (Brief title) | A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2M | |
| Region |
|
|
| Condition | |||
| Condition | Prostate cancer / Urothelial carcinoma / Renal cell carcinoma / Testicular cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Safety and pharmacokinetics research on 89Zr-Df-IAB2M in Japan as a new PET diagnostic tracer |
| Basic objectives2 | Others |
| Basic objectives -Others | Safety, Efficacy/Pharmacokinetics |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | Safety:
Subjective and Objective symptom, Vital data, Clinical tests, Radiation exposure, Adverse events |
| Key secondary outcomes | 1) Pharmacokinetics
2) Detection of cancer focus 3) PET imaging condition 4) Imaging of tumor neovascular |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of unapproved drug | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Patient is over 20 years old at the time of informed consent.
(2) Karnofsky Performance Status (KPS) is 70 or over (3) Patients who have the following clinical examination AST or ALT is 2.5 fold higher than normal range T-Bil is 1.5 fold higher than normal range Serum albumin is more than 2..0 g/dl Serum creatinine is1.5 fold or less than normal range Creatinine clearance is more than 60 mL/min |
|||
| Key exclusion criteria | (1) In a clinical trial, patients who need to receive the new treatment
(2) Patinets with severe pulmonary, renal, gastrointestinal, hematological or psychonurological disease (3) Patients whose doctors determined as inadequate for the study |
|||
| Target sample size | 15 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroyuki Nishiyama |
| Organization | Faculty of Medicine, University of Tsukuba |
| Division name | Department of Urology |
| Address | 1-1-1 Tennodai, Tsukuba, Ibaraki |
| TEL | 029-853-3223 |
| nishiuro@md.tsukuba.ac.jp | |
| Public contact | |
| Name of contact person | Akira Joraku |
| Organization | Faculty of Medicine, University of Tsukuba |
| Division name | Department of Urology |
| Address | 1-1-1 Tennodai, Tsukuba, Ibaraki |
| TEL | 029-853-3223 |
| Homepage URL | |
| joruroa@md.tsukuba.ac.jp | |
| Sponsor | |
| Institute | University of Tsukuba |
| Institute | |
| Department | |
| Funding Source | |
| Organization | University of Tsukuba |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | TSUKUBA Imaging Center
ImaginAb, Inc. |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 筑波大学附属病院(茨城県)University of Tsukuba Hospital(Ibaraki)
つくば画像検査センター(茨城県)TSUKUBA Imaging Center(Ibaraki) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017839 |